Feasibility and Satisfaction of Using NET VITALS Self-assessment Tool Among Patients With Neuroendocrine Tumors.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
01 04 2022
01 04 2022
Historique:
entrez:
1
7
2022
pubmed:
2
7
2022
medline:
6
7
2022
Statut:
ppublish
Résumé
There is a lack of effective patient education regarding diagnosis/treatment of neuroendocrine tumors (NETs), possibly related to their rare incidence. In this cross-sectional survey study, NET patients attending the 2019 Annual Los Angeles NET Education Conference were approached to complete NET VITALS, a self-assessment tool gauging patients' perception/awareness of their NET diagnosis/treatment, and a satisfaction survey. Feasibility of NET VITALS, patient satisfaction with NET VITALS, and patients' perception/awareness of their NET diagnosis/treatment were evaluated. This analysis included 68 patients (median age, 63 years; 47.1% gastrointestinal NETs; 88.2% metastatic disease). Participation was 88.3% (68/77), with a median of 85.7% of items completed (range, 61.9%-100.0%). More than 30% of the patients answered "Don't know/Not familiar"/left blank questions related to tumor characteristics, years of symptoms, and liver-directed therapies. In addition, 69.5% of the patients did not feel sufficient information about NETs was provided at diagnosis. Overall, 67.8% of the patients felt that NET VITALS provides topics to discuss with providers and 76.3% would recommend NET VITALS to others. NET VITALS is a feasible and acceptable self-assessment tool to potentially help patients improve communication about their NET diagnosis/treatment with their physician. Further studies will examine NET VITALS' generalizability and discuss its incorporation into clinical care.
Identifiants
pubmed: 35775639
doi: 10.1097/MPA.0000000000002034
pii: 00006676-202204000-00006
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-324Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
D.L. reports research funding to his institution from AstraZeneca and Brooklyn ImmunoTherapeutics. He serves as a consultant and has received honoraria from Adagene, Advanced Accelerator Applications, Bayer, Coherus, Eisai, Exelixis, Genentech, Ipsen Biopharmaceuticals, Lexicon, Merck, MiNA Therapeutics, QED, Servier, Sun Pharma, Taiho, and TerSera Therapeutics, all outside the submitted work. The remaining authors declare no conflict of interest.
Références
Yao JC, Hassan M, Phan A, et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol . 2008;26:3063–3072.
Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol . 2017;3:1335–1342.
Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database. 2021. Available at: http://www.seer.cancer.gov . Accessed July 13, 2021.
Boudreaux JP, Klimstra DS, Hassan MM, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the jejunum, ileum, appendix, and cecum. Pancreas . 2010;39:753–766.
Koo J, Dhall D. Problems with the diagnosis of metastatic neuroendocrine neoplasms. Which diagnostic criteria should we use to determine tumor origin and help guide therapy? Semin Diagn Pathol . 2015;32:456–468.
Attai DJ, Cowher MS, Al-Hamadani M, et al. Twitter social media is an effective tool for breast cancer patient education and support: patient-reported outcomes by survey. J Med Internet Res . 2015;17:e188.
Yang T, Tan T, Yang J, et al. The impact of using three-dimensional printed liver models for patient education. J Int Med Res . 2018;46:1570–1578.
Coughlin CC, Pérez M, Kumar MG, et al. Skin cancer risk education in pediatric solid organ transplant patients: an evaluation of knowledge, behavior, and perceptions over time. Pediatr Transplant . 2017;21:e12817.
Guevara Y, Gaber R, Clayman ML, et al. Sun protection education for diverse audiences: need for skin cancer pictures. J Cancer Educ . 2015;30:187–189.
Singh S, Granberg D, Wolin E, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol . 2017;3:43–53.
Wolin EM, Leyden J, Goldstein G, et al. Patient-reported experience of diagnosis, management, and burden of neuroendocrine tumors: Results from a large patient survey in the United States. Pancreas . 2017;46:639–647.
Los Angeles Carcinoid Neuroendocrine Tumor Society. NET VITALS—your NET communication tool. 2021. Available at: https://www.lacnets.org/netvitals . Accessed July 13, 2021.
Los Angeles Carcinoid Neuroendocrine Tumor Society. Mission statement. 2020. Available at: https://www.lacnets.org/mission-history/ . Accessed October 16, 2020.
Feinberg Y, Law C, Singh S, et al. Patient experiences of having a neuroendocrine tumour: a qualitative study. Eur J Oncol Nurs . 2013;17:541–545.
Engqvist Boman L, Sandelin K, Wengström Y, et al. Patients' learning and understanding during their breast cancer trajectory. Patient Educ Couns . 2017;100:795–804.
Momoh AO, Griffith KA, Hawley ST, et al. Patterns and correlates of knowledge, communication, and receipt of breast reconstruction in a modern population-based cohort of patients with breast cancer. Plast Reconstr Surg . 2019;144:303–313.
Brütting J, Bergmann M, Garzarolli M, et al. Unmet information needs of patients with melanoma in Germany. Melanoma Res . 2019;29:196–204.
Song L, Weaver MA, Chen RC, et al. Associations between patient–provider communication and socio-cultural factors in prostate cancer patients: a cross-sectional evaluation of racial differences. Patient Educ Couns . 2014;97:339–346.
Berger O, Grønberg BH, Loge JH, et al. Cancer patients' knowledge about their disease and treatment before, during and after treatment: a prospective, longitudinal study. BMC Cancer . 2018;18:381.